FORM	4
------	---

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – Rice William G.	I	2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) C/O APTOSE BIOSCIENCES INC., CONSUMERS ROAD, SUITE 1105	0.51	3. Date of Earliest Transaction (Month/Day/Year) 01/18/2022					X_Officer (give title below) Other (specify below) Chair, President & CEO				
(Street) TORONTO, A6 M2J 4R3	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Beneficial				
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number of		6. Date Exercisable and 7. Tit		7. Title and	itle and Amount 8. Price		9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transaction Derivative		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect		
Security	or Exercise	(Month/Day/Year)	any	Code Securities		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial		
(Instr. 3)	Price of		(Month/Day/Year)					(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership		
	Derivative			or Disposed of								2	(Instr. 4)		
	Security			(D) (Instr. 3, 4,						0	Direct (D)				
										1	or Indirect				
					and 5)							Transaction(s)	< / <		
											Amount		(Instr. 4)	(Instr. 4)	
									Expiration	Title	or				
								Exercisable	Date		Number				
				Code	V	(A)	(D)				of Shares				
Employee										~					
Option	\$ 1.34	01/18/2022		А		700.000		<u>(1)</u>	01/17/2032	Common Shares	700.000	\$ 0	700.000	D	
Grant	φ 1.5 Ι	01/10/2022		11		,00,000			01/1//2052	Shares	,,	ΨΟ	,00,000	D	
Grant															

Reporting Owners

		Relationships						
	Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
(Rice William G. C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 FORONTO, A6 M2J 4R3	Х		Chair, President & CEO				

Signatures

/s/ Janet Clennett as attorney-in-fact for William G. Rice	01/20/2022	
Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Fifty percent (50%) of the options vest on 1/18/2023; the remaining 50% vest as follows: 1/3 on 1/18/2024; 1/3 on 1/18/2025; and 1/3 on 1/18/2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.